Drug Profile
Bupivacaine - Acasti Pharma
Alternative Names: Bupivacaine HCl metered spray - Acasti Pharma; Bupivacaine hydrochloride topical - Acasti Pharma; GTX 101 - Acasti Pharma; GTX101Latest Information Update: 26 Dec 2022
Price :
$50
*
At a glance
- Originator Grace Therapeutics
- Developer Acasti Pharma
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Postherpetic neuralgia
Most Recent Events
- 22 Dec 2022 Safety and pharmacokinetics data from a phase I trial in Postherpetic neuralgia released by Acasti Pharma
- 22 Dec 2022 Acasti Pharma plans a multiple ascending dose trial in healthy subjects to potentially be followed by an efficacy assessment phase II trial in Postherpetic neuralgia
- 27 Jul 2022 Phase-I clinical trials in Postherpetic neuralgia (In volunteers, In adults) in Canada (Topical) (NCT05517486)